Profile of:

Philippe Carron

Full name: Philippe Carron

Current country: Belgium

Membership level: Full

Type of membership: Member

Number of publications: 14

Association of anatomical variants of the sacroiliac joint with bone marrow edema in patients with axial spondyloarthritis. (2023)

Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension (2023)

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question (2023)

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease (2023)

A machine learning pipeline for predicting bone marrow oedema along the sacroiliac joints on magnetic resonance imaging (2023)

Neural network algorithm for detection of erosions and ankylosis on CT of the sacroiliac joints: multicentre development and validation of diagnostic accuracy (2023)

Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations (2023)

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update (2023)

Use of Imaging in Axial Spondyloarthritis for Diagnosis and Assessment of Disease Remission in the Year 2022 (2022)

Unexpected impact of COVID-19 lockdown on spinal mobility and health perception in spondyloarthritis. (2021)

The value of magnetic resonance imaging for assessing disease extent and prediction of relapse in early peripheral spondyloarthritis. (2021)

Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis – OMERACT validation of two whole-body MRI methods. (2021)

Joint and entheseal inflammation in the knee region in spondyloarthritis – reliability and responsiveness of two OMERACT whole-body MRI scores. (2021)

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. (2021)